Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-cash Items (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Non-cash Items for 12 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 86.3% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, down 86.3% year-over-year, with the annual reading at $2.3 million for FY2025, 86.3% down from the prior year.
  • Non-cash Items hit $2.3 million in Q4 2025 for Coherus Oncology, down from $17.0 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $61.4 million in Q4 2021 to a low of $2.3 million in Q4 2025.
  • Historically, Non-cash Items has averaged $33.9 million across 5 years, with a median of $37.4 million in 2023.
  • Biggest five-year swings in Non-cash Items: dropped 10.36% in 2021 and later tumbled 86.3% in 2025.
  • Year by year, Non-cash Items stood at $61.4 million in 2021, then fell by 16.12% to $51.5 million in 2022, then dropped by 27.38% to $37.4 million in 2023, then crashed by 54.52% to $17.0 million in 2024, then crashed by 86.3% to $2.3 million in 2025.
  • Business Quant data shows Non-cash Items for CHRS at $2.3 million in Q4 2025, $17.0 million in Q4 2024, and $37.4 million in Q4 2023.